We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
76
Whitehawk Therapeutics
WHWK
$263M
$7.92M 0.19%
4,166,000
– –
VSTM icon
77
Verastem
VSTM
$654M
$7.84M 0.18%
+887,561
New +$6.61M
BTSG icon
78
BrightSpring Health Services
BTSG
$11.7B
$7.8M 0.18%
+263,800
New +$6.13M
ALMS
79
Alumis Inc
ALMS
$2.9B
$7.69M 0.18%
1,926,423
– –
BCRX icon
80
BioCryst Pharmaceuticals
BCRX
$2.51B
$6.84M 0.16%
+901,500
New +$7.51M
MIST icon
81
Milestone Pharmaceuticals
MIST
$144M
$6.44M 0.15%
+3,221,828
New +$5.67M
RPTX
82
DELISTED
Repare Therapeutics
RPTX
$5.85M 0.14%
3,322,488
– –
APLS
83
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$5.66M 0.13%
250,000
+200,000
+400% +$4.66M
NSPR icon
84
InspireMD
NSPR
$39.8M
$5.14M 0.12%
2,133,405
– –
BIOA
85
BioAge Labs
BIOA
$443M
$4.65M 0.11%
790,901
-131,058
-14% -$614K
JBIO
86
Jade Biosciences
JBIO
$1.33B
$4.58M 0.11%
531,163
– –
QTTB icon
87
Q32 Bio
QTTB
$447M
$4.46M 0.1%
2,252,987
– –
BTSG icon
88
CALL
BrightSpring Health Services
BTSG
$11.7B
$4.43M 0.1%
+150,000
New +$3.49M
DFTX
89
Definium Therapeutics
DFTX
$5.51B
$4.34M 0.1%
+367,824
New +$3.43M
CRNX icon
90
PUT
Crinetics Pharmaceuticals
CRNX
$9B
$4.17M 0.1%
+100,000
New +$3.2M
CELC icon
91
Celcuity
CELC
$4.33B
$4.15M 0.1%
+84,020
New +$3.36M
IMTX icon
92
Immatics
IMTX
$1.44B
$3.98M 0.09%
466,601
-253,300
-35% -$1.56M
SRRK icon
93
CALL
Scholar Rock
SRRK
$7.04B
$3.72M 0.09%
+100,000
New +$3.5M
TGTX icon
94
CALL
TG Therapeutics
TGTX
$8.26B
$3.61M 0.08%
+100,000
New +$3.29M
IMA
95
ImageneBio Inc
IMA
$60.6M
$3.09M 0.07%
378,556
+83,609
+28% +$1.11M
INSM icon
96
Insmed
INSM
$25.9B
$1.94M 0.05%
13,459
– –
ATAI icon
97
AtaiBeckley Inc
ATAI
$2.7B
$1.84M 0.04%
+347,000
New +$1.41M
KRRO icon
98
Korro Bio
KRRO
$190M
$1.55M 0.04%
32,400
– –
MURA
99
DELISTED
Mural Oncology
MURA
$1.22M 0.03%
588,800
– –
TRAW icon
100
Traws Pharma
TRAW
$9.07M
$1.12M 0.03%
605,531
– –
1 2 3
4
5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.